CDK4 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-0633R-Cy5.5-100uL |
| Product Name | CDK4 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Cow, Pig |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CDK4 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 1019 |
| Swiss Prot | P11802 |
| Subcellular location | Cytoplasm, Nucleus, Cell membrane |
| Synonyms | CMM3; PSK-J3; Cyclin-dependent kinase 4; Cell division protein kinase 4; CDK4 |
| Background | Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is CDK4 Polyclonal Antibody, Cy5.5 Conjugated (BS-0633R-CY5-5) validated for, and at what dilution?
BS-0633R-CY5-5 is validated for WB (1:300-5000); FCM (1:20-100); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does CDK4 Polyclonal Antibody, Cy5.5 Conjugated (BS-0633R-CY5-5) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Cow, Pig.
How should BS-0633R-CY5-5 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise CDK4 Polyclonal Antibody, Cy5.5 Conjugated (BS-0633R-CY5-5)?
KLH conjugated synthetic peptide derived from human CDK4
What are the excitation and emission wavelengths of the Cy5.5 conjugate (BS-0633R-CY5-5)?
Cy5.5 on BS-0633R-CY5-5: excitation / emission 675nm/694nm.